Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.

Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J.

Invest New Drugs. 2017 Feb;35(1):95-104. doi: 10.1007/s10637-016-0406-z. Epub 2016 Nov 16.

2.

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.

Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau KM, Yu MS, Yang Y, Hsieh RK, Chang JY, Shan YS, Chao Y, Chen LT; Taiwan Cooperative Oncology Group.

Ann Oncol. 2015 May;26(5):943-9. doi: 10.1093/annonc/mdv035. Epub 2015 Jan 28.

PMID:
25632066
3.

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO, Park YS, Kang WK, Lim HY.

Lancet Oncol. 2012 Feb;13(2):181-8. doi: 10.1016/S1470-2045(11)70301-1. Epub 2011 Dec 20. Erratum in: Lancet Oncol. 2012 Feb;13(2):e49. Chang, Joung Soon [corrected to Jang, Joung Soon].

PMID:
22192731
4.

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer.

Kim ST, Jang KT, Lee SJ, Jang HL, Lee J, Park SH, Park YS, Lim HY, Kang WK, Park JO.

BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y.

5.

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S, Gruenberger T.

Lancet Oncol. 2010 Dec;11(12):1142-8. doi: 10.1016/S1470-2045(10)70247-3. Epub 2010 Nov 9.

PMID:
21071270
6.

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.

Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.

7.

Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.

Hwang IG, Jang JS, Oh SY, Rho MH, Lee S, Park YS, Park JO, Nam EM, Lee HR, Jun HJ, Chi KC.

Cancer Chemother Pharmacol. 2015 Apr;75(4):757-62. doi: 10.1007/s00280-015-2691-1. Epub 2015 Feb 13.

PMID:
25677446
8.

Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.

Li J, Merl M, Lee MX, Kaley K, Saif MW.

Expert Opin Drug Saf. 2010 Mar;9(2):207-13. doi: 10.1517/14740330903555181.

PMID:
20095915
9.

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.

Wang JP, Wu CY, Yeh YC, Shyr YM, Wu YY, Kuo CY, Hung YP, Chen MH, Lee WP, Luo JC, Chao Y, Li CP.

Oncotarget. 2015 Jul 20;6(20):18162-73.

10.

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX.

Br J Cancer. 2014 Jul 29;111(3):430-6. doi: 10.1038/bjc.2014.343. Epub 2014 Jun 24.

11.

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.

Van Cutsem E, Verslype C, Beale P, Clarke S, Bugat R, Rakhit A, Fettner SH, Brennscheidt U, Feyereislova A, Delord JP.

Ann Oncol. 2008 Feb;19(2):332-9. Epub 2007 Nov 6.

PMID:
17986625
12.

A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.

Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BH.

Am J Clin Oncol. 2013 Jun;36(3):250-3. doi: 10.1097/COC.0b013e3182467f22.

13.

Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.

Jang JS, Lim HY, Hwang IG, Song HS, Yoo N, Yoon S, Kim YH, Park E, Byun JH, Lee MA, Oh SJ, Lee KH, Kim BS, Oh SC, Kim SY, Lee SJ.

Cancer Chemother Pharmacol. 2010 Mar;65(4):641-7. doi: 10.1007/s00280-009-1069-7. Epub 2009 Aug 4.

PMID:
19652971
14.

INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.

Patt YZ, Murad W, Fekrazad MH, Baron AD, Bansal P, Boumber Y, Steinberg K, Lee SJ, Bedrick E, Du R, Lee FC.

Cancer Med. 2017 Sep;6(9):2042-2051. doi: 10.1002/cam4.1138. Epub 2017 Aug 11.

15.

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.

LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, Robinson E, Lubner SJ.

Invest New Drugs. 2013 Aug;31(4):943-8. doi: 10.1007/s10637-012-9916-5. Epub 2012 Dec 21.

16.

A phase II study of outpatient biweekly gemcitabine-oxaliplatin in advanced biliary tract carcinomas.

Halim A, Ebrahim MA, Saleh Y.

Jpn J Clin Oncol. 2011 Feb;41(2):217-24. doi: 10.1093/jjco/hyq207. Epub 2010 Nov 8.

PMID:
21062755
17.

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.

Rubovszky G, Láng I, Ganofszky E, Horváth Z, Juhos E, Nagy T, Szabó E, Szentirmay Z, Budai B, Hitre E.

Eur J Cancer. 2013 Dec;49(18):3806-12. doi: 10.1016/j.ejca.2013.07.143. Epub 2013 Sep 2.

PMID:
24007821
18.

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.

Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV.

Lancet Oncol. 2010 Jan;11(1):48-54. doi: 10.1016/S1470-2045(09)70333-X. Epub 2009 Nov 20.

PMID:
19932054
19.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD.

J Clin Oncol. 2005 May 20;23(15):3509-16.

PMID:
15908661
20.

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.

Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H.

J Clin Oncol. 2017 Oct 10;35(29):3330-3337. doi: 10.1200/JCO.2017.72.6463. Epub 2017 Aug 17.

PMID:
28817370

Supplemental Content

Support Center